Silvan Tuerkcan
Stock Analyst at Citizens
(4.32)
# 365
Out of 5,148 analysts
176
Total ratings
48.28%
Success rate
19.36%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $60.77 | +41.52% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $42.03 | +35.62% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $5.84 | +71.23% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $10.00 | +110.00% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $15.44 | +36.01% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.53 | +76.60% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $10.83 | +103.14% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.35 | +344.44% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $12.27 | +177.10% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $33.04 | +36.20% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $41.03 | +21.86% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $6.20 | +141.94% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $4.66 | +28.76% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.76 | +56.25% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $15.90 | +654.72% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.53 | +1,011.11% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.29 | +74.67% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $9.79 | +114.50% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.94 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.80 | +57.89% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $70.98 | +294.48% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.21 | +76.30% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $60.77
Upside: +41.52%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $42.03
Upside: +35.62%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $5.84
Upside: +71.23%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $10.00
Upside: +110.00%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $15.44
Upside: +36.01%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.53
Upside: +76.60%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $10.83
Upside: +103.14%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.35
Upside: +344.44%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $12.27
Upside: +177.10%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $33.04
Upside: +36.20%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $41.03
Upside: +21.86%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.20
Upside: +141.94%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.66
Upside: +28.76%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.76
Upside: +56.25%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $15.90
Upside: +654.72%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.53
Upside: +1,011.11%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.29
Upside: +74.67%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $9.79
Upside: +114.50%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.94
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.80
Upside: +57.89%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $70.98
Upside: +294.48%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.21
Upside: +76.30%